Temocillin Pharmacokinetic in Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Gram-Negative Bacterial InfectionsRenal Failure Chronic Requiring Hemodialysis
Interventions
DRUG

temocillin PK/PD in haemodialysis

Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).

Trial Locations (2)

1020

Louvain Drug Research Institute (LDRI), Brussels

8000

AZ Sint-Jan Brugge Oostende AV, Bruges

All Listed Sponsors
collaborator

Paul Tulkens, Louvain drug research institute, belgium

UNKNOWN

collaborator

Francoise Van Bambeke, Louvain drug research institute, belgium

UNKNOWN

collaborator

Ana Miranda Bastos, Louvain drug research institute, belgium

UNKNOWN

lead

AZ Sint-Jan AV

OTHER

NCT02285075 - Temocillin Pharmacokinetic in Hemodialysis | Biotech Hunter | Biotech Hunter